User login
Oncolytic viruses (OVs) are proving to be a promising modality in anticancer therapy. They selectively grow, replicate within, and kill tumor cells while leaving alone untransformed cells. But OVs, such as the respiratory enteric orphan viruses (or reoviruses), have been hampered by neutralizing antireoviral antibodies, which block the viruses from binding to cellular surface receptors, inhibiting viral infection and replication. Researchers from Guizhou Medical University in China and Stanford University in California may have found a solution: a novel strategy using cytokine-induced killer (CIK) cells—which also have antitumor activity—as the delivery system.
Related: Advances in Targeted Therapy for Breast Cancer
Reoviruses have been shown to infect and use peripheral blood mononuclear cells (PBMCs) to reach tumors. Combining cytokine-induced killer cells (developed from PBMCs) with a reovirus could be the way in, the researchers theorized. Their strategy relies on cell carriage—the capacity of some OVs to be “carried” by immune cells to the tumor, where they selectively infect and kill tumor cells.
The researchers found that CIK cells provided cell carriage to the reovirus, which exerted an oncolytic effect on tumor cells but not CIK cells. Moreover, the CIK cells promoted reovirus infection of tumor cells in the presence of neutralizing antibodies. At the same time, the reovirus infection boosted the power of the CIK cells.
Related: Potential New Targeted Treatment for Chondrosarcoma
The researchers’ findings support the idea that reoviruseas and CIK cells are both potent antitumor agents and are “superior as a combination strategy.”
Source:
Zhao X, Ouyang W, Chester C, Long S, Wang N, He Z. PLoS One. 2017;12(9):e0184816.
doi: 10.1371/journal.pone.0184816.
Oncolytic viruses (OVs) are proving to be a promising modality in anticancer therapy. They selectively grow, replicate within, and kill tumor cells while leaving alone untransformed cells. But OVs, such as the respiratory enteric orphan viruses (or reoviruses), have been hampered by neutralizing antireoviral antibodies, which block the viruses from binding to cellular surface receptors, inhibiting viral infection and replication. Researchers from Guizhou Medical University in China and Stanford University in California may have found a solution: a novel strategy using cytokine-induced killer (CIK) cells—which also have antitumor activity—as the delivery system.
Related: Advances in Targeted Therapy for Breast Cancer
Reoviruses have been shown to infect and use peripheral blood mononuclear cells (PBMCs) to reach tumors. Combining cytokine-induced killer cells (developed from PBMCs) with a reovirus could be the way in, the researchers theorized. Their strategy relies on cell carriage—the capacity of some OVs to be “carried” by immune cells to the tumor, where they selectively infect and kill tumor cells.
The researchers found that CIK cells provided cell carriage to the reovirus, which exerted an oncolytic effect on tumor cells but not CIK cells. Moreover, the CIK cells promoted reovirus infection of tumor cells in the presence of neutralizing antibodies. At the same time, the reovirus infection boosted the power of the CIK cells.
Related: Potential New Targeted Treatment for Chondrosarcoma
The researchers’ findings support the idea that reoviruseas and CIK cells are both potent antitumor agents and are “superior as a combination strategy.”
Source:
Zhao X, Ouyang W, Chester C, Long S, Wang N, He Z. PLoS One. 2017;12(9):e0184816.
doi: 10.1371/journal.pone.0184816.
Oncolytic viruses (OVs) are proving to be a promising modality in anticancer therapy. They selectively grow, replicate within, and kill tumor cells while leaving alone untransformed cells. But OVs, such as the respiratory enteric orphan viruses (or reoviruses), have been hampered by neutralizing antireoviral antibodies, which block the viruses from binding to cellular surface receptors, inhibiting viral infection and replication. Researchers from Guizhou Medical University in China and Stanford University in California may have found a solution: a novel strategy using cytokine-induced killer (CIK) cells—which also have antitumor activity—as the delivery system.
Related: Advances in Targeted Therapy for Breast Cancer
Reoviruses have been shown to infect and use peripheral blood mononuclear cells (PBMCs) to reach tumors. Combining cytokine-induced killer cells (developed from PBMCs) with a reovirus could be the way in, the researchers theorized. Their strategy relies on cell carriage—the capacity of some OVs to be “carried” by immune cells to the tumor, where they selectively infect and kill tumor cells.
The researchers found that CIK cells provided cell carriage to the reovirus, which exerted an oncolytic effect on tumor cells but not CIK cells. Moreover, the CIK cells promoted reovirus infection of tumor cells in the presence of neutralizing antibodies. At the same time, the reovirus infection boosted the power of the CIK cells.
Related: Potential New Targeted Treatment for Chondrosarcoma
The researchers’ findings support the idea that reoviruseas and CIK cells are both potent antitumor agents and are “superior as a combination strategy.”
Source:
Zhao X, Ouyang W, Chester C, Long S, Wang N, He Z. PLoS One. 2017;12(9):e0184816.
doi: 10.1371/journal.pone.0184816.